Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02016846
Other study ID # 0209-13
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received December 15, 2013
Last updated December 22, 2013
Start date January 2014

Study information

Verified date December 2013
Source Rabin Medical Center
Contact Amit Tirosh, MD
Phone +972.50.8191078
Email tiroshamit@gmail.com
Is FDA regulated No
Health authority Israel: Clalit Health Services
Study type Interventional

Clinical Trial Summary

Glucocorticoids therapy exposes the patient to an increased risk for diabetes morbidity. However, there is no proven preventive therapy. GLP-1-RA has shown to improve glucose metabolism in healthy volunteers treated with glucocorticoids. We assume that GLP-1-RA will improve glucose metabolism in patients with high risk for diabetes morbidity, treated with glucocorticoids.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 36
Est. completion date
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria:

- Planned treatment with T. Prednisone in dosage >0.5 mg/kg for two weeks or more.

- Age >18 years

- Body mass index >27 kg/m2 OR 1st degree relative with type 2 diabetes mellitus OR hypertension OR hyperlipidemia OR gestational diabetes in the past OR diagnosis of polycystic ovary syndrome.

Exclusion criteria:

- Glycosylated hemoglobin A1c >6.5%

- Diagnosis of diabetes mellitus or treatment with anti-glycemic drug

- Pancreatitis (acute or chronic) in the past

- Active malignancy

- Medullary thyroid carcinoma or multiple endocrine neoplasm type 2 of the patient or of 1st degree relative

- Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Liraglutide

Placebo


Locations

Country Name City State
Israel Rabin Medical Center, Beilinson Campus Petah Tiqva

Sponsors (1)

Lead Sponsor Collaborator
Rabin Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glucose levels 2 hours after 75 gr OGTT 6 weeks No